About: Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test
Creator	Groop, Leif De Marinis, Yang Bläckberg, Anna Bompada, Pradeep Ekström, Ola Eriksson, Karl-Fredrik Gonçalves, Isabel Hansson, Ola Rasmussen, Magnus Sunnerhagen, Torgny Svensson, Joel Yang, Runtao
Source	MedRxiv
abstract	The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Lifting confinement restriction and resuming to normality depends greatly on COVID-19 immunity screening. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n=45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. We also studied antibody response in relation to time after symptom onset and disease severity, and observed an increase in antibody reactivity and distinct distribution patterns of IgM and IgG following disease progression. The total IgM and IgG detection is 63% in patients with < 2 weeks from disease onset; 85% in non-hospitalized patients with > 2 weeks disease duration; and 91% in hospitalized patients with > 2 weeks disease duration. We also compared different blood sample types and suggest a potentially higher sensitivity by serum/plasma comparing with whole blood measurement. To study the specificity of the test, we used 69 sera/plasma samples collected between 2016-2018 prior to the COVID-19 pandemic, and obtained a test specificity of 97%. In summary, our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our study supports that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1101/2020.08.05.20168815
has license	medrxiv
sha1sum (hex)	83e8cbe4ee47f927b1214ae431a5e787e410f803
schema:url	https://doi.org/10.1101/2020.08.05.20168815
resource representing a document's title	Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test
resource representing a document's body	covid:83e8cbe4ee47f927b1214ae431a5e787e410f803#body_text
is schema:about of	named entity 'test' named entity 'collected' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'blood' named entity 'expertise' named entity 'Lund University' named entity 'study' named entity 'PhD' named entity 'SARS-CoV-2' named entity 'CRISIS' named entity 'IGG' named entity 'COMPARING' named entity 'RATE' named entity 'PROGRESS' named entity 'CREATED' named entity 'PRINCIPLE INVESTIGATOR' named entity 'UNIVERSITY' named entity 'TOTAL' named entity 'GENOME EDITING' named entity 'SYMPTOM ONSET' named entity 'ANTIBODY' named entity 'AREAS' named entity 'HIGHER' named entity 'INVOLVED' named entity 'SCREENING' named entity 'ELECTROPHYSIOLOGY' named entity 'MEDICINE' named entity 'MAPPED' named entity 'RESOLVED' named entity '2 WEEKS' named entity 'REUSE' named entity 'STUDENT' named entity 'HOSPITALIZED PATIENTS' named entity 'DIAGNOSTIC' named entity 'SERA' named entity 'CAUSES' named entity 'CHAIR' named entity 'COMPREHENSIVE' named entity 'SERUM' named entity 'rapid' named entity 'COVID-19' named entity 'patients' named entity 'patients' named entity 'PhD' named entity 'compared' named entity 'focus' named entity 'validation' named entity 'infectious diseases' named entity 'medicine' named entity 'IgG' named entity 'weeks' named entity 'involved' named entity 'test' named entity 'specificity' named entity 'patterns' named entity 'IgM' named entity 'weeks' named entity 'observed' named entity 'infection' named entity 'detection' named entity 'electrophysiology' named entity 'COVID-19' named entity 'risk' named entity 'areas' named entity 'IgG' named entity 'principle investigator' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'COVID-19' named entity 'antibody' named entity 'COVID-19 pandemic' named entity 'COVID' named entity 'coronavirus disease 2019'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software